Verastem (VSTM) Total Non-Current Liabilities (2012 - 2026)
Verastem's (VSTM) quarterly Total Non-Current Liabilities came in at $146.0 million in Q1 2026, up 33.5% year-on-year from $109.4 million in Q1 2025, and down 4.93% quarter-over-quarter from $153.6 million in Q4 2025.
Verastem (VSTM) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Verastem's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $146.0 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 33.5% year-over-year to $146.0 million in Q1 2026; TTM through Mar 2026 was $146.0 million, a 33.5% increase from a year earlier, with the FY2025 full-year figure at $153.6 million, up 112.65% from the prior year.
- Total Non-Current Liabilities declined to $146.0 million in Q1 2026 per VSTM's latest filing, from $153.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $153.6 million in Q4 2025 and bottomed at $68.0 million in Q3 2024.
- The 4-year median for Total Non-Current Liabilities is $126.7 million (2025), against an average of $114.7 million.
- Across the five-year window, Total Non-Current Liabilities decreased 5.21% in 2024 and surged 112.65% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $71.8 million in 2023, then advanced by 0.65% to $72.2 million in 2024, then jumped by 112.65% to $153.6 million in 2025, then retreated by 4.93% to $146.0 million in 2026.
- Per Business Quant, the three latest VSTM Total Non-Current Liabilities figures stand at $146.0 million (Q1 2026), $153.6 million (Q4 2025), and $144.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Verastem | 166.09 Mn | -31.73 Mn | 15.90 Mn | 146.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.03 Mn |
| Dec 31, 2025 | 153.60 Mn |
| Sep 30, 2025 | 144.09 Mn |
| Jun 30, 2025 | 152.66 Mn |
| Mar 31, 2025 | 109.39 Mn |
| Dec 31, 2024 | 72.23 Mn |
| Sep 30, 2024 | 68.02 Mn |
| Sep 30, 2023 | 71.76 Mn |
| Jun 30, 2020 | 83.29 Mn |
| Mar 31, 2020 | 84.30 Mn |
| Dec 31, 2019 | 137.00 Mn |
| Sep 30, 2019 | 170.21 Mn |
| Jun 30, 2019 | 168.73 Mn |
| Mar 31, 2019 | 154.41 Mn |
| Dec 31, 2018 | 151.81 Mn |
| Sep 30, 2018 | 74.98 Mn |
| Jun 30, 2018 | 45.65 Mn |
| Mar 31, 2018 | 29.76 Mn |
| Dec 31, 2017 | 31.96 Mn |
| Sep 30, 2017 | 21.95 Mn |